Amneal Pharmaceuticals Inc (NASDAQ: AMRX) started the day on Wednesday, with a price decrease of -2.12% at $8.32, before settling in for the price of $8.50 at the close. Taking a more long-term approach, AMRX posted a 52-week range of $3.36-$8.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 7.85% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -23.74%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -6.36%. This publicly-traded company’s shares outstanding now amounts to $306.56 million, simultaneously with a float of $119.85 million. The organization now has a market capitalization sitting at $2.58 billion.
Amneal Pharmaceuticals Inc (AMRX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Drug Manufacturers – Specialty & Generic Industry. Amneal Pharmaceuticals Inc’s current insider ownership accounts for 61.28%, in contrast to 39.32% institutional ownership. According to the most recent insider trade that took place on Aug 15 ’24, this organization’s Executive Vice President sold 40,225 shares at the rate of 7.85, making the entire transaction reach 315,766 in total value, affecting insider ownership by 256,670. Preceding that transaction, on Aug 14 ’24, Company’s Executive Vice President sold 22,486 for 7.81, making the whole transaction’s value amount to 175,616. This particular insider is now the holder of 296,895 in total.
Amneal Pharmaceuticals Inc (AMRX) Earnings and Revenue Records
Amneal Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -6.36% and is forecasted to reach 0.70 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 3.00% through the next 5 years, which can be compared against the -23.74% growth it accomplished over the previous five years trading on the market.
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Trading Performance Indicators
Let’s observe the current performance indicators for Amneal Pharmaceuticals Inc (AMRX). It’s Quick Ratio in the last reported quarter now stands at 0.82. The Stock has managed to achieve an average true range (ATR) of 0.26. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.99. Similarly, its price to free cash flow for trailing twelve months is now 57.22.
In the same vein, AMRX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.62, a figure that is expected to reach 0.13 in the next quarter, and analysts are predicting that it will be 0.70 at the market close of one year from today.
